Table 1 Demographic and clinical characteristics, and patterns of care among Indigenous and non-indigenous cancer patients, Queensland, Australia 1998–2004
|  | Indigenous (n = 956) N (%) | Non-Indigenous (n = 869) N (%) | P-value |
|---|---|---|---|
Age | Â | Â | Â |
18- 39Â years | 108 (11) | 91 (11) | 0.852 |
40 – 59 years | 421 (44) | 387 (45) | |
60 + years | 427 (45) | 391 (45) | |
Sex | Â | Â | Â |
male | 436 (46) | 393 (45) | 0.870 |
female | 520 (54) | 476 (55) | |
Area of remoteness index | Â | Â | Â |
Highly accessible/Accessible | 329 (34) | 369 (43) | <0.001 |
Moderately accessible | 370 (39) | 325 (37) | |
Remote/Highly remote | 257 (27) | 175 (20) | |
Socioeconomic status (SEIFA) | Â | Â | Â |
1 Most disadvantaged | 354 (37) | 215 (25) | <0.001 |
2 Disadvantaged | 238 (25) | 261 (30) | |
3 Intermediate advantage | 213 (22) | 219 (25) | |
4 Advantaged | 111 (12) | 136 (16) | |
5 Most advantaged | 39 (4) | 36 (4) | |
Cancer stage at diagnosis* | Â | Â | Â |
Localised cancer | 316 (38) | 336 (45) | 0.030 |
Regional Spread | 240 (29) | 197 (26) | |
Distant metastasis | 275 (33) | 221 (29) | |
Unknown or not applicable | 125 | 115 | Â |
Comorbidity score** | Â | Â | Â |
0 | 481 (50) | 601 (69) | <0.001 |
1 | 256 (27) | 143 (16) | |
2+ | 219 (23) | 125 (14) | |
Diabetes | Â | Â | Â |
No | 669 (70) | 785 (90) | <0.001 |
Yes | 287 (30) | 84 (10) | |
HbA1C levels recorded | (N = 113) | (N = 18) |  |
Equal to or less than 6.5% | 36 (32) | 7 (39) | 0.485 |
Greater than 6.5% | 77 (68) | 11 (61) | |
Any cancer treatment | Â | Â | Â |
Given treatment | 716 (75) | 745 (86) | <0.001 |
No treatment or treatment unknown | 240 (25) | 124 (14) | |
Curative cancer treatment £ | N = 556 | N = 533 |  |
Given treatment | 400(72) | 417 (78) | 0.030 |
No treatment or treatment unknown | 153 (28) | 116 (22) | |
Surgery | Â | Â | Â |
Surgery | 494 (52) | 549 (64) | <0.001 |
No surgery or treatment unknown | 462 (48) | 320 (36) | |
Chemotherapy | Â | Â | Â |
Chemotherapy | 269 (28) | 321 (37) | <0.001 |
No chemotherapy or treatment unknown | 687 (72) | 548 (63) | |
Chemotherapy completed ^ | N = 160 | N = 190 |  |
Completed | 122 (76) | 152 (80) | 0.530 |
Not completed or treatment unknown | 38 (24) | 38 (20) | |
Radiotherapy | Â | Â | Â |
Radiotherapy | 325 (34) | 359 (41) | 0.001 |
No Radiotherapy or not sure | 631 (66) | 510 (59) | |
Age | Â | Â | Â |
18- 39Â years | 108 (11) | 91 (11) | 0.852 |
40 – 59 years | 421 (44) | 387 (45) | |
60 + years | 427 (45) | 391 (45) | |
Sex | Â | Â | Â |
male | 436 (46) | 393 (45) | 0.870 |
female | 520 (54) | 476 (55) | |
Area of remoteness index | Â | Â | Â |
Highly accessible/Accessible | 329 (34) | 369 (43) | <0.001 |
Moderately accessible | 370 (39) | 325 (37) | |
Remote/Highly remote | 257 (27) | 175 (20) | |
Socioeconomic status ( SEIFA ) | Â | Â | Â |
1 Most disadvantaged | 354 (37) | 215 (25) | <0.001 |
2 Disadvantaged | 238 (25) | 261 (30) | |
3 Intermediate advantage | 213 (22) | 219 (25) | |
4 Advantaged | 111 (12) | 136 (16) | |
5 Most advantaged | 39 (4) | 36 (4) | |
Cancer site and IDC code # | Â | Â | Â |
Bronchus and lung (C33- C34) | 187 (20) | 173 (20) | 0.9 |
Breast (C56) | 111 (12) | 107 (12) | |
Colorectal and small intestine (C17-20) | 87 (9) | 89 (10) | |
Head and neck (C00- C14) | 83 (9) | 84 (10) | |
Lymphoma and leukaemia (C42 & C77/ M 01- M10) | 61 (6) | 55 (6) | |
Cervix (C53) | 56 (6) | 49 (6) | |
Liver (C22) | 48 (5) | 30 (4) | |
Other cancers | 41 (4) | 32 (4) | |
Renal tract (C64- C67) | 40 (4) | 46 (5) | |
Corpus uteri (C54) | 38 (4) | 36 (4) | |
Oesophagus (C15) | 31 (3) | 21 (2) | |
Other cancers | 47 (5) | 35 (4) | |
Ovary (C56) | 29 (3) | 29 (3) | |
Unknown primary (C80) | 29 (3) | 17 (2) | |
Stomach (16) | 27 (3) | 23 (3) | |
Prostate (C61) | 25 (3) | 17 (2) | |
Pancreas (C25) | 22 (2) | 25 (3) | |
Thyroid (C73) | 21 (2) | 14 (2) | |
Central Nervous System (C71) | 13 (1) | 12 (1) | |
Melanoma (C44 or M12)) | 7 (1) | 10 (1) | |
Cancer stage at diagnosis* | Â | Â | Â |
Localised cancer | 316 (38) | 336 (45) | 0.030 |
Regional Spread | 240 (29) | 197 (26) | |
Distant metastasis | 275 (33) | 221 (29) | |
Unknown or not applicable | 125 | 115 | Â |
Comorbidity score** | Â | Â | Â |
0 | 481 (50) | 601 (69) | <0.001 |
1 | 256 (27) | 143 (16) | |
2+ | 219 (23) | 125 (14) | |
Diabetes | Â | Â | Â |
No | 669 (70) | 785 (90) | <0.001 |
Yes | 287 (30) | 84 (10) | |
HbA1C levels recorded | (N = 113) | (N = 18) |  |
Equal to or less than 6.5% | 36 (32) | 7 (39) | 0.485 |
Greater than 6.5% | 77 (68) | 11 (61) | |
Any cancer treatment | Â | Â | Â |
Given treatment | 716 (75) | 745 (86) | <0.001 |
No treatment or treatment unknown | 240 (25) | 124 (14) | |
Curative cancer treatment £ | N = 556 | N = 533 |  |
Given treatment | 400 (72) | 417 (78) | 0.030 |
No treatment or treatment unknown | 153 (28) | 116 (22) | |
Surgery | Â | Â | Â |
Surgery | 494 (52) | 549 (64) | <0.001 |
No surgery or treatment unknown | 462 (48) | 320 (36) | |
Chemotherapy | Â | Â | Â |
Chemotherapy | 269 (28) | 321 (37) | <0.001 |
No chemotherapy or treatment unknown | 687 (72) | 548 (63) | |
Chemotherapy completed ^ | N = 160 | N = 190 |  |
Completed | 122 (76) | 152 (80) | 0.530 |
Not completed or treatment unknown | 38 (24) | 38 (20) | |
Radiotherapy | Â | Â | Â |
Radiotherapy | 325 (34) | 359 (41) | 0.001 |
No Radiotherapy or treatment unknown | 631 (66) | 510 (59) |